17,261 trials
Malignant Pleural Mesothelioma
Primary: To Determine the Rate of Clinical Benefit (i.e. Rate of Complete or Partial Response Plus Stable Disease) at 16 Weeks for Patients With Malignant Mesothelioma Treated…
Tinnitus
Primary: Tinnitus Handicap Inventory (THI) — 37.9; 45.1; 42.67; 26.0 units on a scale of 0-100 — p=<0.05
B-cell Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma · Prolymphocyctic Leukemia
Primary: Percentage of Participants Achieving Response — 92.6; 80.0; 70.8 percentage of participants
Chronic Obstructive Pulmonary Disease
Primary: Ratio of TNF Alpha at Week 6 to Baseline — 1.37; 1.21 ratio
Chronic Hepatitis C
Primary: Adverse Event Profile of Repeated Dosing of CF102 — 6; 2; 2; 4 participants
Autism Spectrum Disorder
Primary: Maximum Tolerated Dose (MTD) — 0.40 IU / kg
Meningitis, Meningococcal
Primary: Percentage of Participants With at Least 4-fold Rise in Recombinant Lipoprotein 2086 (rLP2086) Specific Serum Bactericidal Assay Using Human Complement (hSBA) Titer…
Adenocarcinoma of the Prostate · Hormone-resistant Prostate Cancer · Recurrent Prostate Cancer
Primary: PFS Proportion Achieved With STA-9090 in Men With CRPC Who Have Received Prior Docetaxel Based Therapy — 0.0 proportion with 6+ months PFS
Extensive Stage Lung Small Cell Carcinoma · Recurrent Lung Small Cell Carcinoma
Primary: Maximum Tolerated of Sunitinib Combined With Cisplatin and Etoposide (Phase I) — 25 mg/day
Fibromyalgia
Primary: Change in Mu-opioid Receptor Occupancy — 0.2352; .0015 Unitless: binding potential is Bmax/Kd
Mantle Cell Lymphoma · Lymphoma
Primary: Response Rate — 52; 0; 19; 5 percentage of participants
Allergic Rhinitis · Rhinoconjunctivitis
Primary: Combined Rhinoconjunctivitis Symptom and Medication Score — 0.86; 0.64; 0.72 score (maximum=3)
Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) — 1.4; 3.0 months — p=<0.0001
Plaque Psoriasis
Primary: Percentage of Participants Achieving a 75% Reduction in the Psoriasis Area and Severity Index (PASI75) at Week 12 — 62.50; 33.33 percentage of participants
Influenza
Primary: Number of Seroconverted Subjects for Haemagglutination Inhibition (HI) Antibodies Against Each of the Four Vaccine Influenza Strains of FluLaval® Quadrivalent Vaccine…